These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 8481674)

  • 1. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.
    Case DC; Gerber MC; Gams RA; Crawford J; Votaw ML; Higano CS; Pruitt BT; Gould J
    Leuk Lymphoma; 1993; 10 Suppl():73-9. PubMed ID: 8481674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma.
    Case DC; Gerber MC; Gams RA; Crawford J; Votaw ML; Higano CS; Pruitt BT; Gould J
    Cancer Res; 1992 Jul; 52(14):3871-4. PubMed ID: 1617662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II study of oral idarubicin in favorable histology non-Hodgkin's lymphoma.
    Case DC; Hayes DM; Gerber M; Gams R; Ervin TJ; Dorsk BM
    Cancer Res; 1990 Nov; 50(21):6833-5. PubMed ID: 2208149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of a combination of idarubicin, etoposide and intermediate-dose cytosine arabinoside as salvage therapy in relapsing or resistant unfavorable lymphoma.
    Brusamolino E; Passamonti F; Pagnucco G; Castagnola C; Lazzarino M; Bernasconi C
    Haematologica; 1998 Apr; 83(4):323-8. PubMed ID: 9592982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
    Reiser M; Schnell R; Straub G; Borchmann P; Wilhelm M; Ubelacker R; Wörmann B; Münch R; Diehl V; Engert A
    Leuk Lymphoma; 1998 Oct; 31(3-4):359-66. PubMed ID: 9869200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma.
    Zinzani PL; Martelli M; Storti S; Musso M; Cantonetti M; Leone G; Cajozzo A; Papa G; Iannitto E; Perrotti A
    Leuk Lymphoma; 1995 Oct; 19(3-4):329-35. PubMed ID: 8535227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of oral idarubicin (4-demethoxidaunorubicin) in previously untreated elderly patients with non-Hodgkin's lymphoma.
    Errante D; Sorio R; Zagonel V; Carbone A; Monfardini S; Tirelli U
    Am J Clin Oncol; 1991 Jun; 14(3):243-5. PubMed ID: 2031512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idarubicin and high dose cytarabine: a new salvage treatment for refractory or relapsing non-Hodgkin's lymphoma.
    Dufour P; Mors R; Berthaud P; Lamy T; Bergerat JP; Herbrecht R; Maloisel F; Audhuy B; Lioure B; Giron C; Hurteloup P; Oberling F
    Leuk Lymphoma; 1996 Jul; 22(3-4):329-34. PubMed ID: 8819082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin's lymphoma.
    Engert A; Schnell R; Küpper F; Reiser M; Engelhard M; Wilhelm M; Lathan B; Baltes-Engler S; Winterhalter B; Scheulen ME; Dederichs B; Tesch H; Wörmann B; Diehl V
    Leuk Lymphoma; 1997 Feb; 24(5-6):513-22. PubMed ID: 9086441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of infusional cyclophosphamide, idarubicin, and etoposide in poor prognosis non-Hodgkin's lymphoma.
    Salman H; Perez A; Sparano JA; Ratech H; Negassa A; Hopkins U; Villani G; Fuks J; Wiernik PH
    Am J Clin Oncol; 2003 Aug; 26(4):338-43. PubMed ID: 12902881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary treatment of low-grade non-Hodgkin's lymphoma using an all oral anthracycline-containing regimen, chlorambucil, idarubicin, dexamethasone (CID)--a phase II study.
    Taylor PR; Jackson GH; Galloway MJ; Soukop M; Tinegate H; Angus B; Proctor SJ
    Cancer Chemother Pharmacol; 2000; 46(1):63-8. PubMed ID: 10912580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
    Garay G; Dupont J; Dragosky M; Nucifora E; Cacchione R; Schnidrig P; Fernández J; Abel-Alzueta ; Riveros D; Noviello V; Bèguelin R; Campestri R; Albera C; Nicastro M; Triguboff E
    Leuk Lymphoma; 1997 Aug; 26(5-6):595-602. PubMed ID: 9389366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
    Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anthracycline containing regimens in intermediate grade lymphoma. Italian Cooperative Study Group on Intermediate Grade Malignant Lymphoma.
    Zinzani PL; Tura S; Cajozzo A; Leone G; Papa G; Gentilini P; Rossi G; Aitini E; Mandelli F
    Leuk Lymphoma; 1993; 10 Suppl():39-41. PubMed ID: 8481669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of fludarabine, idarubicin and cyclophosphamide (FLUIC) combination regimen for young patients with untreated non-follicular low-grade non-Hodgkin's lymphoma.
    Zinzani PL; Pulsoni A; Gentilini P; Visani G; Perrotti A; Molinari AL; Guardigni L; Tani M; Villivà N; Stefoni V; Alinari L; Martelli M; Bonifazi F; Pileri S; Tura S; Baccarani M
    Leuk Lymphoma; 2004 Sep; 45(9):1815-9. PubMed ID: 15223641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral idarubicin in non-Hodgkin's lymphomas.
    Lopez M; Di Lauro L; Papaldo P
    Invest New Drugs; 1986; 4(3):263-7. PubMed ID: 3469170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trial.
    Taylor PR; White JM; Prescott RJ; Angus B; Galloway MJ; Jackson GH; Lessells AM; Lucraft HH; Summerfield GP; Proctor SJ;
    Leuk Lymphoma; 2006 Nov; 47(11):2321-30. PubMed ID: 17107904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical effect of idarubicin on malignant lymphoma].
    Urabe A; Ohno R; Kuraishi Y; Masaoka T; Ohashi Y; Ogawa M
    Gan To Kagaku Ryoho; 1999 Aug; 26(9):1275-82. PubMed ID: 10478180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemia.
    Gahn B; Brittinger G; Dölken G; Döhner H; Emmerich B; Franke A; Freund M; Huber C; Kuse R; Scholten T; Hiddemann W
    Leuk Lymphoma; 2000 Mar; 37(1-2):169-73. PubMed ID: 10721782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.